Access the world's leading financial data and tools

Subscribe for $2
Overview
Profile

Beam Therapeutics stock

BEAM
US07373V1052
A2PY7P

Price

27.41
Today +/-
-0.23
Today %
-0.87 %

Beam Therapeutics stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Beam Therapeutics stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Beam Therapeutics stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Beam Therapeutics stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Beam Therapeutics's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Beam Therapeutics Stock Price History

DateBeam Therapeutics Price
2/6/202527.41 undefined
2/5/202527.65 undefined
2/4/202527.82 undefined
2/3/202525.75 undefined
2/2/202525.59 undefined
1/30/202525.92 undefined
1/29/202527.28 undefined
1/28/202525.91 undefined
1/27/202525.26 undefined
1/26/202525.91 undefined
1/23/202525.98 undefined
1/22/202526.29 undefined
1/21/202526.39 undefined
1/20/202524.53 undefined
1/16/202523.44 undefined
1/15/202523.40 undefined
1/14/202523.39 undefined
1/13/202523.30 undefined
1/12/202525.54 undefined

Beam Therapeutics Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Beam Therapeutics, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Beam Therapeutics from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Beam Therapeutics’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Beam Therapeutics. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Beam Therapeutics’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Beam Therapeutics’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Beam Therapeutics’s growth potential.

Beam Therapeutics Revenue, EBIT and net profit per share

DateBeam Therapeutics RevenueBeam Therapeutics EBITBeam Therapeutics Net Income
2030e1.5 B undefined0 undefined16.89 M undefined
2029e619.57 M undefined-142.08 M undefined-197.23 M undefined
2028e227.84 M undefined-384.55 M undefined-313.54 M undefined
2027e76.35 M undefined-448.74 M undefined-354.59 M undefined
2026e65.08 M undefined-480.99 M undefined-373.26 M undefined
2025e60.12 M undefined-456.28 M undefined-403.54 M undefined
2024e52.45 M undefined-434.23 M undefined-396.63 M undefined
2023377.71 M undefined-176.49 M undefined-132.53 M undefined
202260.92 M undefined-338.48 M undefined-289.09 M undefined
202151.84 M undefined-392.47 M undefined-370.64 M undefined
202020,000 undefined-132.76 M undefined-195.87 M undefined
201920,000 undefined-75.15 M undefined-91.04 M undefined
20180 undefined-45.74 M undefined-117.33 M undefined
20170 undefined-7.88 M undefined-9.69 M undefined

Beam Therapeutics Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (B)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
20172018201920202021202220232024e2025e2026e2027e2028e2029e2030e
00000.050.060.380.050.060.070.080.230.621.5
-----17.65528.33-86.2115.388.3316.92198.68172.69141.52
--------------
00000000000000
-9-117-91-195-370-289-132-396-403-373-354-313-19716
-1,200.00-22.22114.2989.74-21.89-54.33200.001.77-7.44-5.09-11.58-37.06-108.12
45.3245.3245.3246.7364.2370.0277.150000000
--------------
Details

Keystats

ⓘ

Revenue and Growth

The Beam Therapeutics Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Beam Therapeutics is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (B)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (B)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (B)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (B)RETAINED EARNINGS (M)OTHER EQUITY (k)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (B)
2017201820192020202120222023
             
00.150.090.30.971.081.19
000030000
0000000
0000000
0.11.82.78.77.414.821.17
00.150.090.311.271.091.21
0.316.943.2125.4187234.1237.81
0000000
0000000
0000000
0000000
01.818.31814.514.710.87
0.318.761.5143.4201.5248.8248.67
00.170.160.451.471.341.46
             
5.3251.7302.10.60.70.70.82
00.0100.641.591.792.17
-9.5-124.7-203-397.6-768.3-1,057.4-1,189.89
0000-100-2,400604
0000000
-4.2134.1101245.6826.7733.5981.33
0.77.47.86.37.591.62
0.11.712.222.775.258.4123.96
5.72.87.871.2128.5154.379.51
0000000
013.81.32.12.31.90.48
6.525.729.1102.3213.5223.6205.57
004.45.331.20
0000000
07.421.698.5431.3383.5272.82
07.426103.8434.3384.7272.82
6.533.155.1206.1647.8608.3478.39
00.170.160.451.471.341.46
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Beam Therapeutics provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Beam Therapeutics's financial health and stability.

Assets

Beam Therapeutics's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Beam Therapeutics must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Beam Therapeutics after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Beam Therapeutics's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES ()TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
2017201820192020202120222023
-8-116-78-194-370-289-132
003471420
0000000
010-105111251-116
49220104229130178
0000000
0000000
-2-20-72-95-6622-149
0-13-12-16-46-48-33
0-13-66-100-294-46171
00-54-83-247-412105
0000000
0051-2-2-2
417938322767114279
417941322756111276
---2.00-2.00-8.00--
0000000
1146-97126395-327199
-3.06-33.42-84.52-112.1-113.08-26.42-182.93
0000000

Beam Therapeutics stock margins

The Beam Therapeutics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Beam Therapeutics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Beam Therapeutics.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Beam Therapeutics's sales revenue. A higher gross margin percentage indicates that the Beam Therapeutics retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Beam Therapeutics's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Beam Therapeutics's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Beam Therapeutics's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Beam Therapeutics. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Beam Therapeutics's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Beam Therapeutics Margin History

Beam Therapeutics Gross marginBeam Therapeutics Profit marginBeam Therapeutics EBIT marginBeam Therapeutics Profit margin
2030e0 %0 %1.13 %
2029e0 %-22.93 %-31.83 %
2028e0 %-168.78 %-137.61 %
2027e0 %-587.71 %-464.4 %
2026e0 %-739.12 %-573.58 %
2025e0 %-759.02 %-671.28 %
2024e0 %-827.96 %-756.27 %
20230 %-46.73 %-35.09 %
20220 %-555.61 %-474.54 %
20210 %-757.08 %-714.97 %
20200 %-663,800 %-979,350 %
20190 %-375,750.02 %-455,200 %
20180 %0 %0 %
20170 %0 %0 %

Beam Therapeutics Stock Sales Revenue, EBIT, Earnings per Share

The Beam Therapeutics earnings per share therefore indicates how much revenue Beam Therapeutics has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Beam Therapeutics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Beam Therapeutics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Beam Therapeutics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Beam Therapeutics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Beam Therapeutics Revenue, EBIT and net profit per share

DateBeam Therapeutics Sales per ShareBeam Therapeutics EBIT per shareBeam Therapeutics Earnings per Share
2030e18.05 undefined0 undefined0.2 undefined
2029e7.48 undefined0 undefined-2.38 undefined
2028e2.75 undefined0 undefined-3.79 undefined
2027e0.92 undefined0 undefined-4.28 undefined
2026e0.79 undefined0 undefined-4.51 undefined
2025e0.73 undefined0 undefined-4.87 undefined
2024e0.63 undefined0 undefined-4.79 undefined
20234.9 undefined-2.29 undefined-1.72 undefined
20220.87 undefined-4.83 undefined-4.13 undefined
20210.81 undefined-6.11 undefined-5.77 undefined
20200 undefined-2.84 undefined-4.19 undefined
20190 undefined-1.66 undefined-2.01 undefined
20180 undefined-1.01 undefined-2.59 undefined
20170 undefined-0.17 undefined-0.21 undefined

Beam Therapeutics business model

Beam Therapeutics Inc. is a leading company in genome editing and was founded in 2018. The company is headquartered in Cambridge, Massachusetts, USA, and aims to develop and bring innovative genome editing technologies to the market. Beam Therapeutics' business model is based on developing groundbreaking technologies that improve and simplify genome editing in living cells. These technologies are used in medicine, agriculture, and other industries to cure diseases, increase crop yields, and improve quality of life. Beam Therapeutics is led by an experienced and competent team composed of leading scientists, engineers, and businesspeople in the industry. The company collaborates closely with industry and academic partners to develop innovative solutions for genome editing. Beam Therapeutics has several business units focused on the development of genome editing technologies and products. One of these business units is the development of CRISPR technologies (Clustered Regularly Interspaced Short Palindromic Repeats), which allow for precise and effective modification of DNA. Beam Therapeutics employs Prime Editors, a new technology that enables the removal, insertion, or replacement of specific DNA sequences. Another important business area for Beam Therapeutics is the development of novel gene therapy products. This involves repairing or removing disease-causing genes in the body to accelerate or even achieve complete recovery. The gene therapy products being developed by Beam Therapeutics have the potential to save lives and provide a long-term solution for certain diseases such as cancer, viral infections, and specific genetic disorders. The company collaborates closely with universities, hospitals, and other institutions to drive the development of gene therapy products. Beam Therapeutics strives to revolutionize the gene therapy industry and improve the treatment of diseases through genome editing. Overall, Beam Therapeutics has an impressive track record and has experienced strong growth in recent years. The company has successfully completed multiple funding rounds to advance its research and development and has hired many talented employees to realize its vision. In summary, Beam Therapeutics is a medical technology company specializing in the development of groundbreaking genome editing technologies and products. The company aims to revolutionize genome editing in medicine, agriculture, and other industries and have a positive impact on people's lives. Beam Therapeutics is one of the most popular companies on Eulerpool.com.

Beam Therapeutics SWOT Analysis

Strengths

Beam Therapeutics Inc is equipped with advanced gene editing technologies such as base editing and prime editing, which enable precise modifications to genetic material. This positions the company at the forefront of the gene therapy industry, offering potential treatments for a wide range of genetic diseases.

Beam Therapeutics holds a robust intellectual property portfolio, including numerous patents related to its gene editing technologies. This creates a barrier to entry for competitors and provides the company with long-term exclusivity, enhancing its competitive advantage in the market.

The company is comprised of a talented team of scientists, researchers, and industry experts who possess extensive knowledge and expertise in gene editing and therapeutic development. Their collective skills contribute to the successful execution of Beam Therapeutics' projects and drive innovation within the organization.

Beam Therapeutics has established strategic collaborations and partnerships with leading academic institutions and pharmaceutical companies. These alliances provide access to additional resources, technologies, and expertise, enabling the company to accelerate research and development efforts and expand its product pipeline.

Weaknesses

At present, Beam Therapeutics has a relatively limited product portfolio, with only a few candidates in various stages of development. This restricts the company's revenue potential and increases its dependency on the success of a limited number of therapeutic programs.

As with any gene editing technology, Beam Therapeutics faces regulatory and ethical challenges associated with the use of such technologies in human therapies. The company needs to navigate complex regulatory frameworks and address public concerns surrounding gene manipulation, which could potentially delay product approvals or limit market acceptance.

The gene therapy market is highly competitive, with numerous companies actively pursuing gene editing technologies and therapeutic solutions. Beam Therapeutics faces the challenge of differentiating itself from competitors, both in terms of technological advancements and market positioning, to capture and maintain significant market share.

Opportunities

The demand for gene therapies is expected to increase as the understanding of genetic diseases expands and the need for targeted treatment options becomes more apparent. Beam Therapeutics has the opportunity to leverage its expertise and technology to develop novel therapies to address unmet medical needs.

The versatility of Beam Therapeutics' gene editing technologies allows the company to explore and expand its presence in various therapeutic areas beyond its current focus. By diversifying its product pipeline, the company can tap into new markets and address a wider range of genetic diseases.

Threats

Gene editing technologies, although promising, may carry inherent risks and safety concerns. Any adverse events or unexpected outcomes related to the use of Beam Therapeutics' therapies could lead to setbacks in clinical trials, regulatory challenges, or loss of public trust, impacting the company's overall success.

The biotechnology sector, including gene therapy companies like Beam Therapeutics, often face market volatility influenced by factors such as regulatory changes, healthcare policies, economic conditions, and investor sentiment. Fluctuations in the market can impact the company's financial stability, ability to raise funds, and investor confidence.

Reimbursement for gene therapies is still evolving, and uncertain reimbursement models can pose challenges for the adoption and commercialization of innovative treatments. Beam Therapeutics needs to carefully navigate the reimbursement landscape to ensure adequate pricing and reimbursement coverage for its therapies.

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Beam Therapeutics Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Beam Therapeutics historical P/E ratio, EBIT multiple, and P/S ratio

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Beam Therapeutics shares outstanding

The number of shares was Beam Therapeutics in 2024 — This indicates how many shares 77.152 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Beam Therapeutics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Beam Therapeutics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Beam Therapeutics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Beam Therapeutics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Beam Therapeutics does not pay out any dividends.
Beam Therapeutics does not pay out any dividends.
Beam Therapeutics does not pay out any dividends.
LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2
Unfortunately, there are currently no price targets and forecasts available for Beam Therapeutics.

Beam Therapeutics latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
9/30/2024-1.18 -1.17  (0.76 %)2024 Q3
6/30/2024-1.15 -1.11  (3.5 %)2024 Q2
3/31/2024-1.45 -1.21  (16.31 %)2024 Q1
12/31/2023-1.03 1.73  (267.72 %)2023 Q4
9/30/2023-1.39 -1.22  (12.16 %)2023 Q3
6/30/2023-1.45 -1.08  (25.68 %)2023 Q2
3/31/2023-1.37 -1.33  (2.86 %)2023 Q1
12/31/2022-1.35 -0.54  (60.13 %)2022 Q4
9/30/2022-1.34 -1.56  (-16.5 %)2022 Q3
6/30/2022-1.1 -1.02  (7.25 %)2022 Q2
1
2

Eulerpool ESG Scorecard© for the Beam Therapeutics stock

Eulerpool World ESG Rating (EESG©)

53/ 100

🌱 Environment

57

👫 Social

54

🏛️ Governance

47

Environment

Scope 1 - Direct Emissions
Scope 2 - Indirect emissions from purchased energy
Scope 3 - Indirect emissions within the value chain
Total CO₂ emissions
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather
Pesticides
Palm Oil
Tobacco
Genetically modified organisms
Climate concept
Sustainable forestry
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency

Social

Percentage of female employees
Percentage of women in management
Percentage of Asian employees
Share of Asian management
Percentage of Hispanic/Latino employees
Hispano/Latino Management share
Percentage of Black employees
Black Management Share
Percentage of white employees
White Management Share
Adult content
Alcohol
Weapons
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept
Occupational health and safety
Catholic

Governance (Corporate Governance)

Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Beam Therapeutics shareholders

%
Name
Stocks
Change
Date
9.55576 % Farallon Capital Management, L.L.C.7,913,1233,401,3706/30/2024
9.52339 % The Vanguard Group, Inc.7,886,318321,6116/30/2024
9.20920 % ARK Investment Management LLC7,626,139-556,0356/30/2024
7.03983 % BlackRock Institutional Trust Company, N.A.5,829,686396,3056/30/2024
6.57292 % ARCH Venture Partners5,443,03906/30/2024
5.06844 % Fidelity Management & Research Company LLC4,197,179-483,3716/30/2024
4.74527 % State Street Global Advisors (US)3,929,557437,4029/30/2024
2.73751 % MWG Management, Ltd.2,266,934-80,0006/30/2024
2.68617 % Nikko Asset Management Co., Ltd.2,224,415-137,4026/30/2024
2.18932 % Temasek Holdings Pte. Ltd.1,812,97206/30/2024
1
2
3
4
5
...
10

Beam Therapeutics Executives and Management Board

Mr. John Evans

(45)
Beam Therapeutics Chief Executive Officer, Director (since 2017)
Compensation 9.5 M

Dr. Giuseppe Ciaramella

(54)
Beam Therapeutics President
Compensation 3.17 M

Ms. Terry-Ann Burrell

(46)
Beam Therapeutics Chief Financial Officer, Treasurer
Compensation 2.95 M

Dr. Mark Fishman

(72)
Beam Therapeutics Lead Independent Director
Compensation 452,036

Mr. Graham Cooper

(53)
Beam Therapeutics Independent Director
Compensation 440,165
1
2
3

Beam Therapeutics Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
Editas Medicine Stock
Editas Medicine
SupplierCustomer0,900,990,360,810,900,60
Magenta Therapeu Stock
Magenta Therapeu
SupplierCustomer0,820,970,800,870,690,25
Apellis Pharmaceuticals Stock
Apellis Pharmaceuticals
SupplierCustomer0,810,89-0,25-0,290,250,63
Sana Biotechnology Stock
Sana Biotechnology
SupplierCustomer0,620,83-0,490,720,83
Oxford BioMedica Stock
Oxford BioMedica
SupplierCustomer0,280,780,810,820,850,71
ChemoMetec Stock
ChemoMetec
SupplierCustomer0,010,61-0,580,200,570,69
Pfizer Stock
Pfizer
SupplierCustomer-0,240,88-0,240,34-0,510,28
Verve Therapeutics Stock
Verve Therapeutics
SupplierCustomer-0,250,780,900,92
1

Most common questions regarding Beam Therapeutics

What values and corporate philosophy does Beam Therapeutics represent?

Beam Therapeutics Inc is a leading biotechnology company focused on developing precision genetic medicines using its proprietary base editing platform. The company's values center around innovation, collaboration, and commitment to improving patient lives. Beam Therapeutics is dedicated to advancing the understanding and application of base editing technology to address genetic diseases with unmet medical needs. By harnessing the potential of DNA base editing, the company aims to deliver transformative therapies that can permanently correct genetic mutations at the source. Through its cutting-edge approach and dedication to patient-centric innovation, Beam Therapeutics Inc strives to make a significant impact in the field of genetic medicine.

In which countries and regions is Beam Therapeutics primarily present?

Beam Therapeutics Inc is primarily present in the United States.

What significant milestones has the company Beam Therapeutics achieved?

Beam Therapeutics Inc has achieved significant milestones since its inception. These include the successful completion of their initial public offering (IPO) in 2020, raising substantial funds to support ongoing research and development activities. The company has also made advancements in its proprietary base editing technology platform, which holds great potential for treating a wide range of genetic diseases. Furthermore, Beam Therapeutics has established strategic collaborations with renowned academic institutions and biopharmaceutical companies to expedite the development and commercialization of their innovative therapies. These achievements highlight the company's dedication to revolutionizing healthcare through precise, durable, and efficient genetic medicines.

What is the history and background of the company Beam Therapeutics?

Beam Therapeutics Inc. is a biotechnology company that was founded in 2017. It specializes in developing precision genetic medicines using its proprietary base editing technology. This innovative technology allows for the precise and efficient alteration of individual base pairs within the genome. Beam Therapeutics aims to address a wide range of diseases, including genetic and rare diseases, as well as oncology indications. The company's mission is to create a new class of genetic medicines that offer long-lasting and potentially curative benefits for patients. With its dedicated focus on base editing, Beam Therapeutics is at the forefront of advancing the field of genetic medicine.

Who are the main competitors of Beam Therapeutics in the market?

The main competitors of Beam Therapeutics Inc in the market include Editas Medicine, CRISPR Therapeutics, and Intellia Therapeutics.

In which industries is Beam Therapeutics primarily active?

Beam Therapeutics Inc is primarily active in the biotechnology industry. As a leading biotechnology company, Beam Therapeutics focuses on developing precision genetic medicines using its proprietary base editing platform. By harnessing the power of CRISPR technology, Beam Therapeutics aims to address a wide range of diseases caused by genetic mutations. With its innovative approach, extensive research, and strategic partnerships, Beam Therapeutics is at the forefront of advancements in gene editing and therapeutic solutions.

What is the business model of Beam Therapeutics?

Beam Therapeutics Inc's business model revolves around developing and commercializing precision genetic medicines using its proprietary base editing technology platform. By leveraging CRISPR technology, Beam aims to correct errors at the molecular level by making precise changes to the DNA code, allowing for the treatment of a wide range of diseases. By focusing on a diverse pipeline of therapeutics across multiple disease areas, Beam Therapeutics Inc aims to transform the landscape of genetic medicine and provide innovative solutions for patients in need.

What is the P/E ratio of Beam Therapeutics 2025?

The Beam Therapeutics P/E ratio is -5.24.

What is the P/S ratio of Beam Therapeutics 2025?

The Beam Therapeutics P/S ratio is 35.18.

What is the Quality Investing of Beam Therapeutics?

The Quality Investing for Beam Therapeutics is 3/10.

What is the revenue of Beam Therapeutics 2025?

The expected Beam Therapeutics revenue is 60.12 M USD.

How high is the profit of Beam Therapeutics 2025?

The expected Beam Therapeutics profit is -403.54 M USD.

What is the business model of Beam Therapeutics

Beam Therapeutics Inc is a leading company in the gene therapy industry, specializing in the development of advanced gene editing tools. The company is headquartered in Cambridge, Massachusetts and was founded in 2018. Its unique approach involves using precision gene editing to treat and cure genetic diseases and incurable conditions. Beam Therapeutics has established itself based on the revolutionary BEAM technology platform, which allows for the creation of gene editing tools with extremely high precision. BEAM stands for Base Editing by Advanced Machinery, and it is a type of gene editing that specifically alters individual building blocks in the genome instead of replacing the entire gene. This enables researchers at Beam Therapeutics to treat diseases in the genome with high precision and without size limitations. Beam Therapeutics Inc offers its technology platform in various business areas. The company's core area of focus is the development of the groundbreaking BEAM technology platform, which serves as the foundation for the development of a variety of gene correction tools. These tools enable researchers to target and treat diseases in the genome through precision gene editing. Additionally, Beam Therapeutics Inc also offers the development of gene therapies for specific diseases. For example, the company is working on editing gene sequences associated with cancer, sickle cell anemia, and beta-thalassemia. In collaboration with development partners, gene therapies are being developed and tested to determine the most effective treatment for these conditions. Another business area is the provision of services. Beam Therapeutics Inc offers technical services to its customers, such as genetic screenings. It is also possible to develop custom genome editing tools for research purposes or internal use. Beam Therapeutics Inc has a strong network of partnerships and has entered into agreements with various companies and institutions. The goal of these collaborations is to develop new gene therapies and conduct clinical trials. Furthermore, Beam Therapeutics Inc aims to connect researchers and scientists from around the world to advance developments in gene editing. In conclusion, Beam Therapeutics Inc specializes in the development and commercialization of precision gene editing tools and gene therapies for the treatment of genetic diseases and incurable conditions. The company operates in various business areas and offers unique and innovative solutions to researchers, developers, and customers through its BEAM technology platform.

What is the Beam Therapeutics dividend?

Beam Therapeutics pays a dividend of 0 USD distributed over payouts per year.

How often does Beam Therapeutics pay dividends?

The dividend cannot currently be calculated for Beam Therapeutics or the company does not pay out a dividend.

What is the Beam Therapeutics ISIN?

The ISIN of Beam Therapeutics is US07373V1052.

What is the Beam Therapeutics WKN?

The WKN of Beam Therapeutics is A2PY7P.

What is the Beam Therapeutics ticker?

The ticker of Beam Therapeutics is BEAM.

How much dividend does Beam Therapeutics pay?

Over the past 12 months, Beam Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Beam Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Beam Therapeutics?

The current dividend yield of Beam Therapeutics is .

When does Beam Therapeutics pay dividends?

Beam Therapeutics pays a quarterly dividend. This is distributed in the months of December, March, June, March.

How secure is the dividend of Beam Therapeutics?

Beam Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Beam Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Beam Therapeutics located?

Beam Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Beam Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Beam Therapeutics from 3/3/2014 amounting to 0.225 USD, you needed to have the stock in your portfolio before the ex-date on 2/4/2014.

When did Beam Therapeutics pay the last dividend?

The last dividend was paid out on 3/3/2014.

What was the dividend of Beam Therapeutics in the year 2024?

In the year 2024, Beam Therapeutics distributed 0 USD as dividends.

In which currency does Beam Therapeutics pay out the dividend?

The dividends of Beam Therapeutics are distributed in USD.

All fundamentals about Beam Therapeutics

Our stock analysis for Beam Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Beam Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.